Latest news with #StaarSurgical
Yahoo
07-08-2025
- Business
- Yahoo
Staar Surgical (STAA) Reports Q2 Loss, Beats Revenue Estimates
Staar Surgical (STAA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +87.50%. A quarter ago, it was expected that this maker of implantable lenses would post a loss of $0.59 per share when it actually produced a loss of $0.52, delivering a surprise of +11.86%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $44.32 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.63%. This compares to year-ago revenues of $99 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Staar Surgical shares have added about 11.2% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for Staar Surgical? While Staar Surgical has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Staar Surgical was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.18 on $87.83 million in revenues for the coming quarter and -$0.78 on $258.21 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Becton Dickinson (BDX), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This medical device manufacturer is expected to post quarterly earnings of $3.42 per share in its upcoming report, which represents a year-over-year change of -2.3%. The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. Becton Dickinson's revenues are expected to be $5.48 billion, up 9.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STAAR Surgical Company (STAA) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
06-08-2025
- Business
- Business Insider
Staar Surgical Stock (STAA) Soars on $1.5B Alcon Deal
Staar Surgical (STAA) stock soared on Tuesday after the implantable lenses company reached an agreement with eye care company Alcon (ALC). This will have Alcon acquire all outstanding shares of STAA stock for $28 per share in cash. This represents a 51% premium to the stock's prior closing price and has a total equity value of approximately $1.5 billion. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Stephen Farrell, CEO of Staar Surgical, said, 'As a significantly larger company, Alcon has the capabilities and scale to accelerate EVO ICL adoption and bring our innovative technology to more surgeons and patients worldwide.' Staar Surgical and Alcon expect the deal to close within six to 12 months. It already has the support of both companies' boards of directors. Alcon also expects the deal to be accretive to its earnings in the second year after the deal is complete. Staar Surgical Stock Movement Today Staar Surgical stock was up 44.73% in pre-market trading on Tuesday, following a 4.11% rally yesterday. However, the shares have fallen 23.88% year-to-date and 51.2% over the past 12 months. Today's news came with heavy trading, as some 8 million shares changed hands, compared to a three-month daily average of about 678,000 units. Is Staar Surgical Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Staar Surgical is Hold, based on two Buy, two Hold, and a single Sell rating over the past three months. With that comes an average STAA price target of $19.29, representing a potential 4.33% upside for the shares.
Yahoo
14-05-2025
- Business
- Yahoo
Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended March 2025, Staar Surgical (STAA) reported revenue of $42.59 million, down 45% over the same period last year. EPS came in at -$0.52, compared to $0.06 in the year-ago quarter. The reported revenue represents a surprise of +5.57% over the Zacks Consensus Estimate of $40.34 million. With the consensus EPS estimate being -$0.59, the EPS surprise was +11.86%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Staar Surgical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Geographic Sales- United States: $5.46 million compared to the $5.82 million average estimate based on two analysts. The reported number represents a change of +10.6% year over year. Net Geographic Sales- Japan: $11.39 million versus $10.54 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change. Net Geographic Sales- China: $0.39 million versus $1.15 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -99% change. View all Key Company Metrics for Staar Surgical here>>>Shares of Staar Surgical have returned +23.5% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STAAR Surgical Company (STAA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Washington Post
07-05-2025
- Business
- Washington Post
Staar Surgical: Q1 Earnings Snapshot
LAKE FOREST, Calif. — LAKE FOREST, Calif. — Staar Surgical Co. (STAA) on Wednesday reported a loss of $54.2 million in its first quarter. The Lake Forest, California-based company said it had a loss of $1.10 per share. Losses, adjusted for restructuring costs and stock option expense, were 52 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 59 cents per share. The maker of implantable lenses posted revenue of $42.6 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $40.3 million. _____
